Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(13%)
Results Posted
40%(2 trials)
Terminated
1(13%)

Phase Distribution

Ph not_applicable
2
25%
Ph phase_2
2
25%
Ph phase_3
1
13%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Recruiting1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 22 (25.0%)
Phase 31 (12.5%)
N/A2 (25.0%)

Trials by Status

completed563%
recruiting113%
terminated113%
unknown113%

Recent Activity

1 active trials
Showing 5 of 8
completedphase_1

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

NCT04643457
recruitingnot_applicable

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

NCT06487832
completedphase_1

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

NCT05496738
completedphase_2

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

NCT02654223
unknownphase_2

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

NCT02661854
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04643457Phase 1

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

Completed
NCT06487832Not Applicable

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

Recruiting
NCT05496738Phase 1

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Completed
NCT02654223Phase 2

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

Completed
NCT02661854Phase 2

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

Unknown
NCT00265980Not Applicable

Leptin in Human Energy and Neuroendocrine Homeostasis

Terminated
NCT01768572Phase 3

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Completed
NCT02220153Phase 1

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8